Cargando…

Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients

Co-infection of Hepatitis B (HBV) and Delta viruses (HDV) represent the most severe form of viral hepatitis. While treatment with pegylated Interferon alpha (PEG-IFNα) is well established, therapy with nucleoside or nucleotide analogues (NA) has been a matter of debate. We aimed to investigate the r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheller, Laura, Hilgard, Gudrun, Anastasiou, Olympia, Dittmer, Ulf, Kahraman, Alisan, Wedemeyer, Heiner, Deterding, Katja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	4500
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284709/ https://www.ncbi.nlm.nih.gov/pubmed/34260535 http://dx.doi.org/10.1097/MD.0000000000026571

Ejemplares similares

Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015)

Impact of Nucleos(t)ide Analogue Combination Therapy on the Estimated Glomerular Filtration Rate in Patients With Chronic Hepatitis B
por: Qi, Xun, et al.
Publicado: (2015)

Effect of nucleos(t)ide analogues on blood lipid profiles in patients with chronic hepatitis B: A cross-sectional survey
por: Chen, Jing Wen, et al.
Publicado: (2022)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015)

Clinical and Virological Aspects of HBV Reactivation: A Focus on Acute Liver Failure
por: Anastasiou, Olympia E., et al.
Publicado: (2019)

The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs
por: Gupta, Nidhi, et al.
Publicado: (2014)

Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy
por: Jiang, Bei, et al.
Publicado: (2022)

Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score
por: Kaneko, Shun, et al.
Publicado: (2020)

Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?
por: Liang, Xieer, et al.
Publicado: (2022)

Course of hepatitis E infection in a patient with rheumatoid arthritis and autoimmune hepatitis: A case report
por: Thodou, Victoria, et al.
Publicado: (2017)

Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B
por: Choe, Jae Young, et al.
Publicado: (2017)

Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg‐Negative CHB
por: Wübbolding, Maximilian, et al.
Publicado: (2020)

TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China
por: Huang, Mingxing, et al.
Publicado: (2017)

A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B
por: Zhou, Jialing, et al.
Publicado: (2016)

Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2021)

A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection
por: Burm, Rani, et al.
Publicado: (2022)

Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos(t)ide analogue
por: Ramji, Alnoor, et al.
Publicado: (2022)

HBV and HDV: New Treatments on the Horizon
por: Zuccaro, Valentina, et al.
Publicado: (2021)

HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation
por: Xie, Yandi, et al.
Publicado: (2021)

Serum HBV RNA Dynamic and Drug Withdrawal Predictor Value in Patients With Chronic HBV Infection on Long-term Nucleos(t)ide Analogue (NA) Therapy
por: Liu, Yayun, et al.
Publicado: (2020)

Corrigendum: Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2022)

Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2011)

Predictors of Sustained Virologic Response after Discontinuation of Nucleos(t)ide Analog Treatment for Chronic Hepatitis B
por: Peng, Jie, et al.
Publicado: (2015)

Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas
por: Wei, Yanyan, et al.
Publicado: (2019)

Predominance of HBV Genotype B and HDV Genotype 1 in Vietnamese Patients with Chronic Hepatitis
por: Hoan, Nghiem Xuan, et al.
Publicado: (2021)

Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues
por: Wang, Yang, et al.
Publicado: (2022)

Chances for cure in chronic HBV/HDV coinfection
por: Iliescu, Gabriela, et al.
Publicado: (2014)

Hepatitis Delta Virus: HDV-HBV Interactions
por: Sureau, Camille
Publicado: (2006)

A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B
por: Lee, Kyung Jae, et al.
Publicado: (2018)

Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population
por: López-Cortés, Luis F., et al.
Publicado: (2014)

Seroconverting nonresponder of high-dose intramuscular HBV vaccine with intradermal HBV vaccine: A case report
por: Das, Manjusha, et al.
Publicado: (2017)

Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection
por: Zhang, Xiaoman, et al.
Publicado: (2019)

Editorial: serum HBV RNA biphasic decline in patients with HBeAg‐positive chronic hepatitis B treated with nucleos(t)ide analogues
por: Ding, Yang, et al.
Publicado: (2020)

Virological and serological features of acute hepatitis B in adults
por: Du, Xiaofei, et al.
Publicado: (2017)

HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining
por: Xu, Xizhan, et al.
Publicado: (2017)

Differential response of HBV envelope-specific CD4(+) T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy
por: Li, Yongyin, et al.
Publicado: (2023)

Management of chronic hepatitis B patients: Efficacy & limitation of nucleos(t)ide analogues
por: Inoue, Jun, et al.
Publicado: (2011)

The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis
por: Cholongitas, Evangelos, et al.
Publicado: (2015)

Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
por: Moreno-Cubero, Elia, et al.
Publicado: (2018)

Distinct histological patterns in chronic hepatitis D with nucleos(t)ide analogue therapy
por: Hercun, Julian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_no744dnj304oqhkb80akmabs02